Phase Ib trial of CB 839, combined with pomalidomide and dexamethasone, in patients with myeloma.

Trial Profile

Phase Ib trial of CB 839, combined with pomalidomide and dexamethasone, in patients with myeloma.

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2015

At a glance

  • Drugs CB 839 (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 13 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top